Viking Therapeutics, Inc. Aktie News

Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstrated unmatched double-digit weight loss in 13 weeks, potentially establishing leadership in the oral obesity drug segment. Despite a robust $714M cash position and a 4/5 conviction rating, risks in...

Biotech stocks and research shares diverged Thursday after reports suggested the FDA will soon require just one pivotal study.

Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Piper Sandler 37th Annual Healthcare Conference. The conference will take place December 2-4, 2025, in New York, New York.

If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.

Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.

Viking Therapeutics stock yo-yoed Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.

Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also could deliver a win for investors.